Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

79.66 -0.25 (-0.31%)
Streaming Delayed Price Updated: 1:07 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Market Jitters: Wall Street Braces for Continued Volatility
The U.S. stock market is once again sending signals of caution, as major indices experienced a notable pullback from their recent record highs in early September 2025. This downturn, following a robust... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure
AstraZeneca's Baxdrostat met all endpoints in a Phase 3 trial, showing sustained blood pressure reductions in patients with resistant hypertension. 
Via Benzinga
AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results
AstraZeneca, on Saturday, unveiled promising results for a new hypertension treatment that aims to help the roughly 650,000 people. 
Via Investor's Business Daily
Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca
Via Stocktwits
AstraZeneca CEO Calls US Drug Pricing Model ‘Unsustainable’ — Pushes for Global Rate Alignment
Via Stocktwits
AstraZeneca Q2 Beats On Cancer Drug Sales, Maintains Guidance — Shares Rise Premarket As Retail Cheers
Via Stocktwits
Looking Into AstraZeneca's Recent Short Interest
 
Via Benzinga
Get insights into the top gainers and losers of Tuesday's after-hours session.
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data
Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026. 
Via Benzinga
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen. 
Via Benzinga
Earnings Scheduled For July 29, 2025
 
Via Benzinga
AstraZeneca Earnings Preview
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing 'Uncompetitive' System
UK drug pricing talks collapsed after the government and pharma firms failed to agree on National Health Service rebates. 
Via Benzinga
J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs
Johnson & Johnson (NYSE: JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs... 
Via Benzinga
Topics Government World Trade
IonQ Expands Quantum IP Portfolio, Surpassing 1,000 Patents And Applications
IonQ, Inc. announces major progress in its IP strategy with new U.S. patents, reinforcing its leadership in quantum computing and potential for commercial advantage. 
Via Benzinga
Topics Intellectual Property
AstraZeneca Launches Home Delivery Service For Its Self-Administrable Flu Vaccine
Flumist can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age. 
Via Stocktwits
White House Eyes Up to 250% Drug Tariffs In Bid To Reclaim US Pharma Supply Chain
White House trade adviser Peter Navarro discusses tariffs on pharma imports under a "Section 232" trade investigation. 
Via Benzinga
Topics World Trade
The Specter of Stagflation: Trump's Tariffs Cast a Long Shadow Over the U.S. Economy
Economists and investors are increasingly sounding the alarm over the growing risk of "stagflation," a perilous economic phenomenon characterized by high inflation coupled with stagnant economic... 
Via MarketMinute
Topics Economy Government Supply Chain
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit
Stagflation Specter Haunts Markets as Economic Data Disappoints
The global financial markets are grappling with a growing sense of unease as recent economic data points to a troubling confluence of high inflation and sluggish growth, rekindling fears of... 
Via MarketMinute
Topics Economy Stocks World Trade
1 Small-Cap Biotech Stock Poised for a Breakout
This developmental biotech is nearing a key inflection point. 
Via The Motley Fool
Topics Economy
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca
Via Stocktwits
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data
Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose. 
Via Benzinga
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. 
Via Benzinga
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Why AstraZeneca Stock Was Topping the Market on Tuesday
Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line. 
Via The Motley Fool
AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook
AstraZeneca posted $14.46 billion in Q2 revenue, reaffirming its 2025 outlook as the FDA advances Imfinzi in gastric cancer. 
Via Benzinga
Topics Earnings
Why Is Micro-Cap AIM ImmunoTech Stock Surging?
AIM ImmunoTech shares rise after DURIPANC trial data show superior survival and safety in metastatic pancreatic cancer patients. 
Via Benzinga
5 Dividend Stocks to Hold for the Next 20 Years
Discover five unstoppable dividend stocks that could pay you for life, and why I wouldn't sell any of them! 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.